Loading clinical trials...
Loading clinical trials...
A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients.
Conditions
Interventions
Voriconazole
Locations
25
United States
Childrens Hospital Los Angeles
Los Angeles, California, United States
Children's Hospital & Research Center Oakland (CHRCO)
Oakland, California, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Children's Pavilion, Virginia Commonwealth University Health System
Richmond, Virginia, United States
Virginia Commonwealth University Health System, Hospital Pharmacy
Richmond, Virginia, United States
Start Date
May 1, 2009
Primary Completion Date
May 1, 2013
Completion Date
May 1, 2013
Last Updated
June 16, 2017
NCT03717623
NCT06382922
NCT06583512
NCT04486885
NCT06028451
NCT01430663
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions